Drugs / C-TIL052A
C-TIL052A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05475847 | Jul 2022 → Jul 2025 | cervical cancer | Fudan University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C-TIL052A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05475847 ↗ |
| Known as | Autologous Tumor Infiltrating Lymphocytes | “Eligible subjects will receive injection of C-TIL052A (Autologous Tumor Infiltrating Lymphocytes, TIL) and interleukin 2 (IL-2) after lymphodepletion.” NCT05475847 ↗ |
| Known as | TIL | “Eligible subjects will receive injection of C-TIL052A (Autologous Tumor Infiltrating Lymphocytes, TIL) and interleukin 2 (IL-2) after lymphodepletion.” NCT05475847 ↗ |
| Modality | Cell therapy | “C-TIL052A cell therapy” NCT05475847 ↗ |
| Route | Other | “C-TIL052A injection” NCT05475847 ↗ |